Nipent (Pentostatin)

Pentostatin inhibits adenosine deaminase, leading to accumulation of deoxyadenosine nucleotides inside lymphoid cells. This interferes with DNA synthesis and repair, causing cell‑cycle arrest and apoptosis of the cancerous B‑cells that drive hairy cell leukemia.

The dose of Nipent is individualized by the prescribing physician based on factors such as the patient’s weight, disease severity, renal and hepatic function, and concurrent therapies. No fixed regimen is provided in public literature.

Safety data for Pentostatin in pregnancy and lactation are limited, and the product is generally classified as contraindicated or to be used only if the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Nipent, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Pentostatin and cladribine are the two main purine analogues used for hairy cell leukemia. Both achieve high remission rates, but Pentostatin may have a slightly different toxicity profile, with a higher incidence of certain hematologic side effects. Choice of therapy depends on patient‑specific factors and physician judgment.

Nipent should be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and do not freeze or shake the solution. If temperature excursions occur, consult the supplier before use.

Nipent is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically over a period of several minutes to an hour, depending on the prescribed protocol and patient tolerance.

The most serious risks include severe neutropenia leading to life‑threatening infections, anaphylactic reactions, pulmonary toxicity, and significant hemorrhage due to thrombocytopenia. Patients should be monitored closely for signs of infection, bleeding, respiratory distress, or allergic response.

Pentostatin should be avoided in patients with known hypersensitivity to the drug, active severe infections, uncontrolled concurrent illnesses, or in those who are pregnant or breastfeeding without a clear benefit. Clinicians must evaluate each individual’s medical history before initiating therapy.